X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (61) 61
index medicus (44) 44
female (43) 43
male (34) 34
middle aged (34) 34
acute myelogenous leukemia (31) 31
hematology (29) 29
aged (28) 28
oncology (28) 28
adult (27) 27
leukemia, myeloid, acute - drug therapy (21) 21
acute myeloid leukemia (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
treatment outcome (20) 20
timed sequential therapy (19) 19
acute myeloid-leukemia (17) 17
chemotherapy (17) 17
cytarabine - administration & dosage (15) 15
timed-sequential chemotherapy (15) 15
acute myelocytic-leukemia (14) 14
acute nonlymphocytic leukemia (14) 14
animals (14) 14
remission induction (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
colony-stimulating factor (11) 11
cytarabine (11) 11
cytosine-arabinoside (11) 11
prognosis (11) 11
adolescent (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
cancer (10) 10
drug administration schedule (10) 10
gait (10) 10
mitoxantrone - administration & dosage (10) 10
aged, 80 and over (9) 9
antineoplastic agents - therapeutic use (9) 9
clinical neurology (9) 9
flavopiridol (9) 9
leukemia (9) 9
neurosciences (9) 9
timed sequential chemotherapy (9) 9
walking (9) 9
acute disease (8) 8
acute myeloblastic-leukemia (8) 8
article (8) 8
combined modality therapy (8) 8
etoposide - administration & dosage (8) 8
leukemia, myeloid - drug therapy (8) 8
mitoxantrone (8) 8
relapse (8) 8
adults (7) 7
analysis (7) 7
cattle (7) 7
chronic lymphocytic-leukemia (7) 7
dose-response relationship, drug (7) 7
follow-up studies (7) 7
parkinson's disease (7) 7
pharmacology & pharmacy (7) 7
phase-ii (7) 7
reproductive biology (7) 7
risk factors (7) 7
stem-cell transplantation (7) 7
therapy (7) 7
acute promyelocytic leukemia (6) 6
aml (6) 6
bone-marrow transplantation (6) 6
falls (6) 6
high-dose cytarabine (6) 6
older patients (6) 6
pregnancy (6) 6
rehabilitation (6) 6
research (6) 6
risk (6) 6
survival analysis (6) 6
trial (6) 6
veterinary sciences (6) 6
young adult (6) 6
acute myeloid leukaemia (5) 5
balance (5) 5
child (5) 5
disease-free survival (5) 5
dose cytosine-arabinoside (5) 5
flavonoids - administration & dosage (5) 5
gonadotropin-releasing-hormone (5) 5
people (5) 5
piperidines - administration & dosage (5) 5
reliability (5) 5
salvage therapy (5) 5
survival rate (5) 5
timed artificial-insemination (5) 5
timed up and go (5) 5
usage (5) 5
age factors (4) 4
agriculture, dairy & animal science (4) 4
autologous transplantation (4) 4
basal ganglia (4) 4
biomedicine (4) 4
bone-marrow-transplantation (4) 4
cell cycle - drug effects (4) 4
cytarabine - adverse effects (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 09/2015, Volume 100, Issue 9, pp. 1172 - 1179
Serial studies have demonstrated that induction therapy with FLAM [flavopiridol 50 mg/m(2) days 1-3, cytarabine 667 mg/m(2)/day continuous infusion days 6-8,... 
ADULT PATIENTS | CYTOSINE-ARABINOSIDE | BONE-MARROW BIOPSY | INDUCTION THERAPY | EUROPEAN LEUKEMIANET | TIMED SEQUENTIAL THERAPY | ACUTE MYELOGENOUS LEUKEMIA | ACUTE MYELOCYTIC-LEUKEMIA | CHRONIC LYMPHOCYTIC-LEUKEMIA | HEMATOLOGY | TUMOR LYSIS SYNDROME
Journal Article
Leukemia Research, ISSN 0145-2126, 2009, Volume 34, Issue 7, pp. 877 - 882
Abstract Flavopiridol, a cyclin-dependent kinase inhibitor, is cytotoxic to leukemic blasts. In a Phase II study, flavopiridol 50 mg/m2 was given by 1-h... 
Hematology, Oncology and Palliative Medicine | AML | Timed sequential therapy | Flavopiridol | Poor risk | KINASE | TRANSCRIPTION | PHASE-II | ACUTE MYELOID-LEUKEMIA | BREAST-CARCINOMA CELLS | CYTOTOXIC SYNERGY | OLDER PATIENTS | ONCOLOGY | CHRONIC LYMPHOCYTIC-LEUKEMIA | INHIBITORS | SCHEDULE | HEMATOLOGY | Sepsis - etiology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Polyamines - therapeutic use | Risk | Flavonoids - adverse effects | Cytarabine - adverse effects | Transplantation, Homologous | Young Adult | Tumor Lysis Syndrome - etiology | Bone Marrow Transplantation | Flavonoids - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Hyperkalemia - prevention & control | Leukemia, Myeloid, Acute - surgery | Sevelamer | Heart Diseases - chemically induced | Mitoxantrone - adverse effects | Tumor Lysis Syndrome - prevention & control | Piperidines - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Combined Modality Therapy | Remission Induction | Cytarabine - administration & dosage | Sepsis - mortality | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Allopurinol - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Hyperkalemia - chemically induced | Aged | Premedication | Index Medicus | Timed Sequential Therapy | Poor Risk
Journal Article
Journal Article
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2019, Volume 94, Issue 1, pp. 111 - 117
To improve the outcome of relapsed/refractory acute myeloid leukemia (AML), a randomized phase II trial of three novel regimens was conducted. Ninety patients... 
CYTOSINE-ARABINOSIDE | CELLS | MITOXANTRONE | TIMED SEQUENTIAL THERAPY | KINASE | ADULTS | PHASE-II | L86-8275 | HEMATOLOGY | FLAVOPIRIDOL
Journal Article
Journal of Experimental and Clinical Cancer Research, ISSN 1756-9966, 02/2018, Volume 37, Issue 1, pp. 36 - 10
Journal Article